The immunopotentiating properties of thymosin in thymectomized, lethally irradiated, bone marrow-reconstituted mice (ThyXBM) were characterized, using footpad sensitivity to The role of the thymus gland in the expression of cellular immunity has only very recently been directly linked to immunocompetent lymphoid cells known as T-lymphocytes (9). The control of these T-lymphocytes may be due to the secretion of a hormonal-type substance known as thymosin (1). This substance, first discovered and isolated from bovine thymus by Goldstein (5), has been shown to be capable of restoring cellular immune functions in both animal and human tests (6, 17, 18) . Investigations in our laboratory over the past few years have fily established the role of cellmediated immunity in marine blastomycosis (16). Mice were shown to develop delayed-type hypersensitivity (DH) reactions to Blastomyces dermatitidis when previously injected with both live and killed yeast cell preparations. When these mice were footpad tested at various time intervals after initial injections of the yeast, they were shown to exhibit an increasing amount of footpad swelling, indicative of a mounting DH response. High levels of DH were also shown to correlate with increased resistance of sensitized mice to live lethal challenges of the yeast. Other studies such as migration inhibition factor production, lymphotoxin activity, and blast transformation correlate with peak DH responses and thus clearly define the important role that the T-cell plays in immunity to blastomycosis.
The role of the thymus gland in the expression of cellular immunity has only very recently been directly linked to immunocompetent lymphoid cells known as T-lymphocytes (9) . The control of these T-lymphocytes may be due to the secretion of a hormonal-type substance known as thymosin (1). This substance, first discovered and isolated from bovine thymus by Goldstein (5) , has been shown to be capable of restoring cellular immune functions in both animal and human tests (6, 17, 18) . Investigations in our laboratory over the past few years have fily established the role of cellmediated immunity in marine blastomycosis (16) . Mice were shown to develop delayed-type hypersensitivity (DH) reactions to Blastomyces dermatitidis when previously injected with both live and killed yeast cell preparations. When these mice were footpad tested at various time intervals after initial injections of the yeast, they were shown to exhibit an increasing amount of footpad swelling, indicative of a mounting DH response. High levels of DH were also shown to correlate with increased resistance of sensitized mice to live lethal challenges of the yeast. Other studies such as migration inhibition factor production, lymphotoxin activity, and blast transformation correlate with peak DH responses and thus clearly define the important role that the T-cell plays in immunity to blastomycosis.
Recently, Collins and Morrison (2) have demonstrated that thymosin can restore DH responses of thymectomized, lethally irradiated, and bone marrow-reconstituted (ThyXBM) mice to a sensitizing dose of sheep erythrocytes. The use of thymosin in the restoration of DH of ThyXBM mice to fungal antigens has not as yet been reported.
The purposes of this investigation were: (i) to determine the effects of T-cell depletion on the induction of the DH response to B. dermatitidis and (ii) to effect an immunopotentiation of these mice by thymosin treatment, utilizing the footpad swelling response ofB. dermatitidis injected mice as a criterion for establishing the into 2 groups of 24. All mice received daily intraperitoneal injections of PSS, beginning on the day of irradiation (2 weeks before day 0) and continuing throughout the duration of the experiment. The first group of animals was injected with the Ag emulsion on days 0 and 7, whereas the second group was similarly injected with the PSS emulsion. Groups of four animals each were footpad tested every 3 days beginning on day 3 and continuing through day 18 . Footpad swelling measurements were recorded for 24 hours post-footpad injection.
Determination of DH of thymosin-treated, ThyXBM mice to B. dermatitidis. To determine whether thymosin treatment of T-cell-depleted mice restored their ability to develop DH responses to B. dermatitidis, an experiment similar to the one described for ThyXBM mice was designed. A total of 48 ThyXBM mice was prepared and divided into two groups of 24. All animals received daily intraperitoneal injections containing 200 ytg of thymosin per injection. Thymosin injections began on the day of irradiation (2 weeks before day 0) and continued throughout the duration of the experiment. The first group of animals was injected with Ag emulsion on days 0 and 7, whereas the second group was similarly injected with PSS emulsion. Four mice from each test group were footpad tested beginning on day 3 and continuing every 3 days through day 18 . Footpad swelling measurements were recorded for 24 h post-footpad injection.
Determination of DH of ThyXBM and thymosin-treated ThyXBM mice on day 12. To further substantiate the immunopotentiating effects of thymosin on ThyXBM mice, two more experiments were designed. Greater numbers of animals were used and a different thymosin treatment schedule was devised. A total of 40 ThyXBM mice was divided into two groups of 20 mice each. The first group of mice received injections of 400 ,g of thymosin per mouse beginning on the day of irradiation (2 weeks before day 0) and continuing on alternating days for the duration of the experiment. 
RESULTS
Induction of the DH response in normal mice. A state of DH as measured by footpad swelling increases was established in mice injected and footpad tested with killed B. dermatitidis. Increasing amounts of footpad swelling were noted in Ag emulsion-injected animals, beginning with those tested on day 6 and continuing with a peak footpad swelling exhibited by animals tested on day 15 . The response then decreased by day 21 (Fig. 1) . Control mice ex-
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hibited minimal footpad swellings on all days tested. Effects of T-cell depletion on the DH response of mice to B. dermatitidi8. The DH response of ThyXBM mice to B. dermatitidis was established. Both Ag emulsion-injected and PSS emulsion-injected ThyXBM animals failed to exhibit increases in footpad thickness on any of the days tested (Fig. 2a) .
Effects of thymosin treatment on the DH response of ThyXBM mice to B. dermatitidis. Thymosin-treated ThyXBM mice were assessed for their ability to develop DH reactions to B. dermatitidis. Thymosin-treated, ThyXBM, Ag emulsion-injected animals exhibited increasing amounts of footpad swelling, beginning with those animals tested on day 6 (Fig. 3a) . (Fig. 3b) . Control mice exhibited minimal footpad swelling.
DH response of thymosin-treated, normal intact mice. The results of a base-line response for the DH response of a normal, intact animal to B. dermatitidis and the effects of thymosin treatment on a normal intact animal are presented here. The footpad response of a normal intact animal is represented by Fig. 4a . The peak response on day 12 occurred at 24 h remained at a high value through 48 h, and decreased by 72 h. Control animals showed minimal footpad swelling. Thymosin treatment of normal intact mice resulted in no enhancement of footpad swelling (Fig. 4b) . Values ofthymosintreated normal intact mice were virtually identical with those of non-thymosin-treated test ThyXBM mice. Control mice exhibited minimum footpad swelling. Measurements were made at the times indicated. Each point represents a mean increase in the footpad thickness of 10 mice. matitidis yeast, whereas low levels of DH result in little, if any, protection. Further studies have indicated that these increasing DH patterns closely follow (i) increases in T-lymphocyte numbers in peripheral blood, (ii) a rise in the number of sensitized T-lymphocytes as measured by blast transformation, and (iii) an increase in lymphotoxin activity. Since such responses are mediated by T-cell presence, it was expected that T-cell-depleted mice would be incapable of developing DH reactions to B. dermatitidis. We did find this to be true, in that ThyXBM mice were unable to mount DH re- (11) necessitated a modified treatment regimen consisting of alternating-day injections of thymosin. Greater numbers of animals insured the validity of the effects of thymosin treatment. The resultant data indicated a 62% increase in footpad thickness of thymosintreated ThyXBM mice over the response as seen in non-thymosin-treated ThyXBM mice. It is important to note that: (i) the infusion of bone marrow into thymectomized mice was alone not sufficient to supply necessary cellular components to participate in DH responses to B. dermatitidis, (ii) the thymosin preparation used in both sets of experiments was capable of influencing bone marrow populations to participate in DH reactions, probably due to T-precursor maturation events (7), and (iii) thymosin had no enhancing effect on the DH response of normal, thymus-bearing mice to B. dermatitidis.
Thymosin has been demonstrated to restore cell-mediated immune functions in immunodeficient animals, such as skin allograft rejection and graft-versus-host reactions (4, 8) . Thymosin is also protective in casein-induced murine amyloidosis and has been reported to enhance T-cell responses of genetically athymic "nude" mice (6, 12) . Recently, thymosin has been sanctioned for use as an experimental drug for treatment of human subjects with primary immunodeficiencies. Clinical studies have demonstrated that thymosin treatments have converted skin testnegative individuals to skin test positive for Candida albicans (5 
